Beyza Aslan

Beyza Aslan

Auto-generated profile, based on publicly available information

Beyza Aslan

Department of Pediatrics, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Open access
TSTevhide Zi̇ver Sarp
Tevhide Zi̇ver Sarp
HDHarika Öykü Dinç
Harika Öykü Dinç
DÖDoğukan Özbey
Doğukan Özbey
SASeher Çeli̇k Akkuş
Seher Çeli̇k Akkuş
BABeyza Aslan
Beyza Aslan
BKBekir Kocazeybek
Bekir Kocazeybek
Objective: Hepatitis Delta Virus is a defective virus that can cause co-infection, superinfection and chronic hepatitis delta infection with Hepatitis B Virus. In this study, it was aimed to retrospectively determine the seroprevalence of HDV infection in patients who applied to Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Microbiology Laboratory with suspected HBV and / or HDV infection between January 2014 and September 2019. Material and Method: HBsAg, anti-HBc IgM, anti HBc (total) HBeAg, anti HBe, anti HBs, anti HDV, HBV DNA and HDV RNA test results were evaluated in the blood of 1374 patients who were admitted with the suspicion of HBV and / or HDV infection between January 2014 and September 2019. Results: The age range of 1374 patients diagnosed with HBV was to 8 to 87 years and 585(%42.6) were female and 789(%57.4) were male. As a result of the analysis, anti HDV positive was detected in 7.9% of 1374 patients. In 2014, it was determined that 1.2% of the patients with positive were acute HBV, 27.3% were chronic HBV and 5.7% were inactive carriers. Between 2015-2019, it was determined that 7.2% of the patients with positive were acute HBV, 8.3% had chronic hepatitis and 9.9% had chronic infection. Although anti-HDV positive was significantly higher in females than males (p <0.05), it was found that there was no statistically significant difference between age groups. Conclusion: Although our study results are similar to the results of prevalence studies conducted in the western region in recent years, they show that the prevalence of anti HDV is in an upward trend, albeit slightly.We think that large-scale studies should be conducted in order to reveal current prevalence data Giriş ve Amaç: Hepatit Delta Virüsü, Hepatit B virüs varlığında koenfeksiyon, süperenfeksiyon ve kronik hepatit delta enfeksiyonu yapabilen defektif bir virüstür. Bu çalışmada, Ocak 2014-Eylül 2019 tarihleri arasında İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi Mikrobiyoloji Laboratuvarına HBV ve/veya HDV enfeksiyonu şüphesi ile başvuran olgularda retrospektif olarak HDV enfeksiyonu seroprevalansının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Ocak 2014-Eylül 2019 tarihleri arasında HBV ve/veya HDV enfeksiyon şüphesi ile başvuran 1374 hasta kanında HBsAg, anti-HBc IgM, anti HBc(total) HBeAg, anti HBe, anti HBs, anti HDV, HBV DNA ve HDV RNA test sonuçları olarak değerlendirilmiştir. Bulgular: Çalışmaya alınan HBV tanılı 1374 hastanın yaşları 8-87 arasında olup, 585’inin(%42.6) kadın, 789’unun(%57.4) erkek olduğu belirlenmiştir. Yapılan analizler sonucunda 1374 hastanın %7.9’unda anti HDV pozitifliği saptanmıştır. 2014 yılında pozitif saptanan hastaların %1.2’sinin akut HBV, %27.3’ünün kronik HBV ve %5.7’sinin inaktif taşıyıcı olduğu belirlenmiştir. 2015-2019 yılları arasında pozitif saptanan hastaların ise %7.2’sinin akut HBV, %8.3’ünün kronik hepatit ve %9.9’unun kronik enfeksiyonu olduğu belirlenmiştir. Anti HDV pozitif saptanan olgular içerisinde kadın bireylerde anti-HDV pozitifliği erkeklere göre anlamlı düzeyde yüksek bulunmakla birlikte(p<0,05), yaş grupları arasında istatistiksel olarak anlamlı düzeyde fark olmadığı saptanmıştır. Sonuç: Çalışma sonuçlarımız son yıllarda batı bölgesinde yapılan prevalans çalışmalarının sonuçlarına benzer bulunmakla birlikte, anti HDV prevalansının az da olsa yükseliş eğiliminde olduğunu göstermektedir. Güncel prevalans verilerinin ortaya koyulabilmesi için geniş çaplı çalışmalar yapılması gerektiğini düşünmekteyiz.

19 May 2026 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SOSinem Oral-Cebeci
Sinem Oral-Cebeci
AZA. Cigdem Aktuglu Zeybek
A. Cigdem Aktuglu Zeybek
BABeyza Aslan
Beyza Aslan
ÖUÖzge Yaren Uysal
Özge Yaren Uysal
MCMehmet Şerif Cansever
Mehmet Şerif Cansever
TZTanyel Zubarioglu
Tanyel Zubarioglu
Acute metabolic decompensation (AMD) is the most life-threatening complication of maple syrup urine disease (MSUD). Recognizing AMD early in the emergency department (ED) is difficult because the most important clinical indicators—neurological manifestations—typically appear late during decompensation, and plasma leucine measurements are frequently delayed. This study aimed to identify laboratory biomarkers that can be obtained quickly and support early AMD detection at ED. This retrospective study included MSUD patients aged 28 days–18 years admitted to a tertiary pediatric ED between 2016 and 2025. Acute neurological deterioration, reduced oral intake, or vomiting with ketosis or plasma leucine levels ≥ 600 µmol/L were defined as AMD. Presenting complaints, duration of hospitalization, treatment modalities, and laboratory investigations were recorded and compared between ED visits with AMD and non-AMD. Among 25 patients, 269 ED visits were analyzed; 79 (29.4%) met AMD criteria. AMD visits were associated with worse clinical outcomes, including higher rates of pediatric intensive care admissions (22% vs. 2.6%) and increased hemodialysis requirements (19% vs. 1.6%). Hyponatremia ( p = 0.005) and hyperuricemia ( p < 0.001) were more prevalent during AMD. Acid–base parameters did not significantly discriminate AMD. Among primary laboratory tests, only serum uric acid was a clinically meaningful predictor (AUC 0.786). A cutoff value of 4.65 mg/dL for uric acid was identified to predict AMD. Conclusion : Serum uric acid is a reliable and clinically practical early predictor of AMD. This readily available marker may enable earlier risk stratification and intervention when leucine results are delayed, potentially improving outcomes in pediatric MSUD. What is Known: • Acute metabolic decompensation (AMD) in pediatric maple syrup urine disease (MSUD) can rapidly lead to encephalopathy, cerebral edema, and permanent neurologic injury. • Early emergency presentations are clinically nonspecific, and plasma leucine—the diagnostic gold standard—is often not available in real time. What is New: • A cutoff value of 4.65 mg/dL for uric acid was identified to predict AMD. • Respiratory symptoms and fever were significantly more frequent in non-AMD visits, suggesting that infectious symptoms alone do not necessarily indicate metabolic instability in MSUD patients.